Eptifibatide,CAS 188627-80-7 CAS NO.188627-80-7

GUANGZHOU MEDCAN PHARMATECH LTD.is a high-tech company engaged in new biopharmaceutical product development, sales, genetic engineering, bioinformatics and other areas of research and development, registered capital of 11,110,000 RMB, the company has established a strategic alliance with more than 10 domestic and foreign pharmaceutical biotechnology and University. Currently, the company's product research and development has been at the forefront of domestic and related fields. In China, the company also received Guangzhou Yuan Tong Pharmaceutical Co., Ltd. and South China Normal University’s support. And It has developed a partnership with the Guangdong Medical College and South China Drug Discovery Centre.
The company has 18 employees, including 4 doctoral,6 master,2 pharmacist, with excellent R & D team, strong technical force, a dynamic management mechanism, first-class management talent and a good financing channel. It is perfectly capable of developing new drugs and advancing technology into economic benefits, to achieve social benefits.
The company’s employees have extensive experience in the synthesis of small molecule drugs, microbial fermentation. In pharmaceutical preparations, the company has developed a variety of dosage forms, including some new formulations such as liquid capsules, controlled release and targeted drug delivery systems. The company has a wealth of export of agents of registered technology, and drug product registration experience of exporting to the EU, the United States, Cuba, Brazil and India. The company established a comprehensive library of fermentation bacteria, with dozens of drugs bacteria fermentation species, such as erythromycin, daptomycin, Nepal, the Secretary and a full set of statins and other bacteria fermentation process. The transfer of technology are welcome to call us

Usage

Eptifibatide is used to reduce the risk of acute cardiac ischemic events (death and/or myocardial infarction) in patients with unstable angina or non-ST-segment-elevation (e.g., non-Q-wave) myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes) both in patients who are to receive non surgery (conservative) medical treatment and those undergoing percutaneous coronary intervention (PCI).

Specifications

Appearance: White to off white  powder

Purity(HPLC): ≥99%

Clarity and solution color: Clear and colorless

Water (K.F): <5.0%

Acetic Acid: <12.0%

Trifluoroacetic Acid: <0.5%

Heavy metal: ≤Ten ppm